LEXICON PHARMACEUTICALS, INC. Logo

LEXICON PHARMACEUTICALS, INC.

Develops gene-based drugs for chronic diseases, including treatments for heart failure.

LXRX | US

Overview

Corporate Details

ISIN(s):
US5288723027
LEI:
Country:
United States of America
Address:
2445 TECHNOLOGY FOREST BLVD., 77381 THE WOODLANDS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company pioneers treatments for serious, chronic conditions by leveraging a unique application of gene science and genetics for drug discovery. Its patient-driven approach aims to develop precise medicines to improve and transform lives. A key product in its portfolio is sotagliflozin, an orally-delivered small molecule drug developed to reduce the risk of cardiovascular death and hospitalization for heart failure. Founded in 1995, Lexicon continues to advance its pipeline of drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all LEXICON PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LEXICON PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LEXICON PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany MYNZ
MAINZ BIOMED N.V. Logo
Develops molecular genetic diagnostic tests for early colorectal cancer detection in the US & Europe.
United States of America MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America MNKD

Talk to a Data Expert

Have a question? We'll get back to you promptly.